CN105796690B - 一种治疗牛皮癣的玫瑰中药组合物及制备方法和应用 - Google Patents
一种治疗牛皮癣的玫瑰中药组合物及制备方法和应用 Download PDFInfo
- Publication number
- CN105796690B CN105796690B CN201610171345.2A CN201610171345A CN105796690B CN 105796690 B CN105796690 B CN 105796690B CN 201610171345 A CN201610171345 A CN 201610171345A CN 105796690 B CN105796690 B CN 105796690B
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- medicine composition
- rose
- psoriasic
- skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 66
- 241000220317 Rosa Species 0.000 title claims abstract description 55
- 239000000203 mixture Substances 0.000 title claims abstract description 53
- 238000002360 preparation method Methods 0.000 title abstract description 10
- 235000014692 zinc oxide Nutrition 0.000 claims abstract description 15
- 229940105847 calamine Drugs 0.000 claims abstract description 14
- 229910052864 hemimorphite Inorganic materials 0.000 claims abstract description 14
- 239000011787 zinc oxide Substances 0.000 claims abstract description 14
- CPYIZQLXMGRKSW-UHFFFAOYSA-N zinc;iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+3].[Fe+3].[Zn+2] CPYIZQLXMGRKSW-UHFFFAOYSA-N 0.000 claims abstract description 12
- 201000004624 Dermatitis Diseases 0.000 claims abstract description 10
- 208000010668 atopic eczema Diseases 0.000 claims abstract description 10
- 230000002682 anti-psoriatic effect Effects 0.000 claims abstract description 4
- 229940030999 antipsoriatics Drugs 0.000 claims abstract description 3
- 241000109329 Rosa xanthina Species 0.000 claims description 6
- 235000004789 Rosa xanthina Nutrition 0.000 claims description 6
- 239000010408 film Substances 0.000 claims description 6
- -1 pulvis Substances 0.000 claims description 3
- 229930003231 vitamin Natural products 0.000 claims description 3
- 239000011782 vitamin Substances 0.000 claims description 3
- 229940088594 vitamin Drugs 0.000 claims description 3
- 235000013343 vitamin Nutrition 0.000 claims description 3
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 3
- 239000000443 aerosol Substances 0.000 claims description 2
- 150000001637 borneol derivatives Chemical class 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 239000000499 gel Substances 0.000 claims description 2
- 239000006210 lotion Substances 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 2
- 150000003870 salicylic acids Chemical class 0.000 claims description 2
- 229940098465 tincture Drugs 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 abstract description 24
- 201000004681 Psoriasis Diseases 0.000 abstract description 18
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 abstract description 17
- 230000000694 effects Effects 0.000 abstract description 17
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 abstract description 13
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 abstract description 13
- 229940116229 borneol Drugs 0.000 abstract description 13
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 abstract description 13
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 abstract description 13
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 abstract description 12
- 229960004889 salicylic acid Drugs 0.000 abstract description 12
- 229930003427 Vitamin E Natural products 0.000 abstract description 8
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 abstract description 8
- 235000019165 vitamin E Nutrition 0.000 abstract description 8
- 239000011709 vitamin E Substances 0.000 abstract description 8
- 229940046009 vitamin E Drugs 0.000 abstract description 8
- 208000017520 skin disease Diseases 0.000 abstract description 6
- 230000001225 therapeutic effect Effects 0.000 abstract description 5
- 208000003251 Pruritus Diseases 0.000 abstract description 4
- 231100000957 no side effect Toxicity 0.000 abstract description 4
- 230000007803 itching Effects 0.000 abstract description 3
- 210000003491 skin Anatomy 0.000 description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 239000012153 distilled water Substances 0.000 description 14
- 239000007788 liquid Substances 0.000 description 10
- 210000002615 epidermis Anatomy 0.000 description 9
- 241000581650 Ivesia Species 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 238000002156 mixing Methods 0.000 description 6
- 239000013589 supplement Substances 0.000 description 6
- 240000003186 Stachytarpheta cayennensis Species 0.000 description 5
- 235000009233 Stachytarpheta cayennensis Nutrition 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Natural products C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
- 238000004821 distillation Methods 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- 210000000498 stratum granulosum Anatomy 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- 230000001139 anti-pruritic effect Effects 0.000 description 3
- 239000003908 antipruritic agent Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000004043 dyeing Methods 0.000 description 3
- 210000001339 epidermal cell Anatomy 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 231100000614 poison Toxicity 0.000 description 3
- 206010040882 skin lesion Diseases 0.000 description 3
- 231100000444 skin lesion Toxicity 0.000 description 3
- 239000003440 toxic substance Substances 0.000 description 3
- WZUVPPKBWHMQCE-XJKSGUPXSA-N (+)-haematoxylin Chemical compound C12=CC(O)=C(O)C=C2C[C@]2(O)[C@H]1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-XJKSGUPXSA-N 0.000 description 2
- 208000010201 Exanthema Diseases 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- 206010033733 Papule Diseases 0.000 description 2
- 208000005775 Parakeratosis Diseases 0.000 description 2
- 241000669298 Pseudaulacaspis pentagona Species 0.000 description 2
- 229940037003 alum Drugs 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 201000005884 exanthem Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000004438 eyesight Effects 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- NALMPLUMOWIVJC-UHFFFAOYSA-N n,n,4-trimethylbenzeneamine oxide Chemical compound CC1=CC=C([N+](C)(C)[O-])C=C1 NALMPLUMOWIVJC-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- 231100000241 scar Toxicity 0.000 description 2
- 239000011697 sodium iodate Substances 0.000 description 2
- 235000015281 sodium iodate Nutrition 0.000 description 2
- 229940032753 sodium iodate Drugs 0.000 description 2
- 229910021532 Calcite Inorganic materials 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 229920000832 Cutin Polymers 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 241000498255 Enterobius vermicularis Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000004044 Hypesthesia Diseases 0.000 description 1
- 208000003367 Hypopigmentation Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 241000593989 Scardinius erythrophthalmus Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 206010065954 Stubbornness Diseases 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 241000130764 Tinea Species 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 206010044684 Trismus Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 240000004922 Vigna radiata Species 0.000 description 1
- 235000010721 Vigna radiata var radiata Nutrition 0.000 description 1
- 235000011469 Vigna radiata var sublobata Nutrition 0.000 description 1
- FMRLDPWIRHBCCC-UHFFFAOYSA-L Zinc carbonate Chemical compound [Zn+2].[O-]C([O-])=O FMRLDPWIRHBCCC-UHFFFAOYSA-L 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000001153 anti-wrinkle effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 208000010217 blepharitis Diseases 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229910001748 carbonate mineral Inorganic materials 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000003778 catagen phase Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 231100000895 deafness Toxicity 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 206010014881 enterobiasis Diseases 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- SEACYXSIPDVVMV-UHFFFAOYSA-L eosin Y Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C([O-])=C(Br)C=C21 SEACYXSIPDVVMV-UHFFFAOYSA-L 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 230000003694 hair properties Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- HLUCICHZHWJHLL-UHFFFAOYSA-N hematein Chemical compound C12=CC=C(O)C(O)=C2OCC2(O)C1=C1C=C(O)C(=O)C=C1C2 HLUCICHZHWJHLL-UHFFFAOYSA-N 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 239000000413 hydrolysate Substances 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 208000034783 hypoesthesia Diseases 0.000 description 1
- 230000003425 hypopigmentation Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 230000036560 skin regeneration Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 125000002640 tocopherol group Chemical group 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 208000025301 tympanitis Diseases 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 239000011667 zinc carbonate Substances 0.000 description 1
- 229910000010 zinc carbonate Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/738—Rosa (rose)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明属于生物医药领域，具体提供了一种治疗牛皮癣的玫瑰中药组合物及制备方法和应用。所述中药组合物含有玫瑰花，水杨酸，维生素E，冰片，炉甘石，具有清热解毒、祛风止痒的功效，对牛皮癣、湿疹及类似皮肤病具有治疗效果，且对皮肤无副作用。可在制备治疗牛皮癣的药物中应用，亦可在制备治疗湿疹的药物中应用。
Description
技术领域
本发明属于生物医药领域，具体涉及一种治疗牛皮癣的玫瑰中药组合物及制备方法和应用。
背景技术
牛皮癣，即寻常型银屑病，是皮肤科中一种常见的慢性炎症性皮肤病，病因尚未明了，患者易于反复发作、具有特征性皮损的皮肤病。其临床特点：表现为红色的丘疹或斑块，初起表现为炎性红色丘疹，约粟粒至绿豆大小，之后融合或逐渐扩大，边界清楚。皮损表面覆盖多层干燥的银白色鳞屑。若轻轻刮除表面鳞屑，逐渐露出一层半透明薄膜，呈淡红色发亮，称为薄膜现象。继续除去薄膜，可点状出血现象。白色鳞屑、发亮薄膜和点状出血是诊断银屑病的三联征。皮损形态：点滴状、钱币状、地图状、环状、带状、泛发性、慢性肥厚性等。好发部位以头皮、四肢伸侧多见，大部分患者为冬重夏轻。病程一般分三期：①进行期：新皮疹不断出现，旧皮疹不断扩大，鳞屑厚，炎症明显，痒感明显，皮肤敏感性增高；②静止期：无新疹，旧疹不容易消退；③退行期：炎症消退，鳞屑减少，皮疹缩小变平，周围出现浅色晕，可遗留暂时性色素减退或沉着。
牛皮癣顽固难治，至今仍被列为世界皮肤科领域的重要研究课题，是全世界皮肤科重点防治疾病之一。在近些年召开的全国牛皮癣防治协作会议上，与会专家一致认为中医药是防治牛皮癣的方向，尤其倡导中药提取物与副作用小的化学成分联合，扬长避短。在现有技术中有多种治疗皮癣的药物。有内服的，如甲氨蝶呤、维A酸类、激素类、免疫抑制剂等。西药有严重的毒副作用，应当避免或减少使用。也有外用的，如皮质类固醇激素软膏等。强效类固醇激素类软膏外用清洁、见效快，但停药易复发，长期使用副作用增多，导致医师倾向不用，或只短期、间断使用，也影响疗效。
针对以上现有技术，本发明现提供一种治疗牛皮癣的玫瑰中药组合物，该中药组合物既具有中药清热、解毒、收敛之功效，又具备止痒、护肤的作用，对牛皮癣、湿疹及类似皮肤病有治疗效果，且对皮肤无副作用。
发明内容
本发明的目的是提供一种治疗牛皮癣的玫瑰中药组合物，所述中药组合物具有清热解毒、祛风止痒的功效，对牛皮癣、湿疹及类似皮肤病具有治疗效果。
本发明的另一个目的是提供上述中药组合物的制备方法。
本发明的另一个目的是提供上述中药组合物的应用。
本发明所述的上述目的是通过以下技术方案实现的：
一种治疗牛皮癣的玫瑰中药组合物，所述中药组合物含有玫瑰花，水杨酸，维生素E，冰片，炉甘石。
一种治疗牛皮癣的玫瑰中药组合物，所述中药组合物含有下述重量比的组分：15-20份玫瑰花，1.5-2.5份水杨酸，0.75-1份维生素E，2.5-5份冰片，12.5-15份炉甘石。
上述中药组合物作为药效成分的药物制剂的剂型为霜剂、乳剂、膏剂、粉剂、洗剂、凝胶剂、气雾剂、涂膜剂、酊剂和醑剂。
一种治疗牛皮癣的玫瑰中药组合物的制备方法，所述制备方法如下：
①将玫瑰花加入100ml蒸馏水中，80℃煎煮蒸馏，浓缩蒸馏液至10ml，制备得到玫瑰花水煎液；
②将炉甘石、冰片研细混匀，过100目筛子，后依次加入水杨酸、维生素E和①中制得的玫瑰花水煎液，补充蒸馏水至100ml，即得所述玫瑰中药组合物。
所述治疗牛皮癣的玫瑰中药组合物可在制备治疗牛皮癣的药物中的应用。
所述治疗牛皮癣的玫瑰中药组合物可在制备治疗湿疹的药物中的应用。
所述的治疗牛皮癣的玫瑰中药组合物在用于治疗使用时，涂抹于患处，一天涂抹2次，一般两三天见效，三个月后基本痊愈。
本发明提供的治疗牛皮癣的玫瑰中药组合物，其药物组方参考了多种医学药典，具体选用的中药、西药药理学基础如下：
玫瑰花：玫瑰花味甘微苦、性微温，归肝、脾、胃经。玫瑰花含有丰富的天然维生素C、蛋白质、矿物质等。具有非常显著的美容护肤作用，能有效美白、柔软肌肤，抚平细纹，预防皱纹，能促进皮肤再生、令肌肤保持弹性与光泽。适合各种肤质，对皮肤干燥、色斑、疤痕、创伤、烧烫伤、晒伤、湿疹、老化皮肤皆有极佳功效。
水杨酸：水杨酸是一种脂溶性的有机酸，具有很强的去角质、清理毛孔的能力，安全性高，且对皮肤的刺激性较果酸更低。分子量较大，可以作用于浅层角质中，不影响活性表皮细胞，在稳定性、刺激程度方面都相对优越。
维生素E：维生素E(Vitamin E)是一种脂溶性维生素，其水解产物为生育酚，是最主要的抗氧化剂之一。主要功效：延缓衰老，有效减少皱纹的产生，保持青春的容貌；改善血液循环、保护组织、降低胆固醇、预防高血压；保护皮肤免受紫外线和污染的伤害，减少疤痕与色素的沉积，加速伤口的愈合等。
冰片：味辛、苦，性凉，归心、肺经。功效：通诸窍，散郁火，去翳明目，消肿止痛。主治：中风口噤，热病神昏，惊痫痰迷，气闭耳聋，喉痹，口疮，中耳炎，痈肿，痔疮，目亦翳膜，蛲虫病。
炉甘石：为碳酸盐类矿物方解石族菱锌矿，主含碳酸锌(ZnCO3)。功能：解毒明目退翳，收湿止痒敛疮。主治：用于目赤肿痛，眼缘赤烂，翳膜胬肉，溃疡不敛，脓水淋漓，湿疮，皮肤瘙痒。
本发明的有益效果：
1.本发明提供的治疗牛皮癣的玫瑰中药组合物组方合理，配伍科学，既具有中药清热、解毒、收敛之功效，又具备止痒、护肤的作用，对牛皮癣、湿疹及类似皮肤病有治疗效果，且对皮肤无副作用。
2.玫瑰花具有的芳香气味，可以使患者心情愉悦，舒缓其因患有牛皮癣造成的负面情绪。
以下通过具体实施例来说明本发明所述的技术方案，实施例是说明性的而不是限定性的，可按照所限定范围列举出若干个实施例，因此在不脱离本发明总体构思下的变化和修改，应属于本发明的保护范围之内。
附图说明
图1玫瑰中药组合物作用7天后小鼠尾部鳞片表皮细胞病理改变(HE染色)
C-空白对照组；H-玫瑰中药组合物高剂量组；M-玫瑰中药组合物中剂量组；L-玫瑰中药组合物低剂量组；B-水杨酸+冰片对照组；G-炉甘石对照组
图2玫瑰中药组合物作用14天后小鼠尾部鳞片表皮细胞病理改变(HE染色)
C-空白对照组；H-玫瑰中药组合物高剂量组；M-玫瑰中药组合物中剂量组；L-玫瑰中药组合物低剂量组；B-水杨酸+冰片对照组；G-炉甘石对照组
具体实施方式
实施例1：治疗牛皮癣的玫瑰中药组合物高剂量组的制备
①将玫瑰花20g加入100ml蒸馏水中，80℃煎煮蒸馏，浓缩蒸馏液至10ml，制备得到玫瑰花水煎液；
②将炉甘石15g、冰片5g研细混匀，过100目筛子，后依次加入水杨酸2.5g、维生素E1g和①中制得的玫瑰花水煎液10ml，补充蒸馏水至100ml，即得所述玫瑰中药组合物。
实施例2：治疗牛皮癣的玫瑰中药组合物中剂量组的制备
①将玫瑰花15g加入100ml蒸馏水中，80℃煎煮蒸馏，浓缩蒸馏液至10ml，制备得到玫瑰花水煎液；
②将炉甘石12.5g、冰片2.5g研细混匀，过100目筛子，后依次加入水杨酸1.5g、维生素E 0.75g和①中制得的玫瑰花水煎液10ml，补充蒸馏水至100ml，即得所述玫瑰中药组合物。
实施例3：治疗牛皮癣的玫瑰中药组合物低剂量组的制备
①将玫瑰花10g加入100ml蒸馏水中，80℃煎煮蒸馏，浓缩蒸馏液至10ml，制备得到玫瑰花水煎液；
②将炉甘石10g、冰片1g研细混匀，过100目筛子，后依次加入水杨酸0.5g、维生素E0.5g和①中制得的玫瑰花水煎液10ml，补充蒸馏水至100ml，即得所述玫瑰中药组合物。
实施例4：本发明所述治疗牛皮癣的玫瑰中药组合物的功效验证
1.生物材料
动物：昆明种小鼠36只，随机分为6组，每组6只，雌雄不限，一级。体质量18-22g。
2.试剂
0.5～1％的伊红酒精溶液：称取伊红Y 0.5～1g，加少量蒸馏水溶解后，再滴加冰醋酸直至浆糊状。以滤纸过滤，将滤渣在烘箱中烤干后，以95％酒精(即工业酒精，如果不怕浪费，用无水乙醇配制也可)100毫升溶解。
苏木素染液配方：(配制3000ml)
苏木精6g，无水乙醇100ml，硫酸铝钾150g，蒸馏水2000ml，碘酸钠1.2g，冰醋酸120ml，甘油900ml。
配制方法：将苏木素溶于无水乙醇，再将硫酸铝钾溶于蒸馏水，溶解后将甘油倾入一起混合，最后加入冰醋酸和碘酸钠。
1％盐酸酒精分化液：将1毫升浓盐酸加入99毫升70％酒精中即可
3.实验组设置
空白对照组：蒸馏水100ml。
玫瑰中药组合物高剂量组：制备如实施例1。
玫瑰中药组合物中剂量组：制备如实施例2。
玫瑰中药组合物低剂量组：制备如实施例3。
水杨酸+冰片对照组：将冰片5g研细混匀，过100目筛子，加入水杨酸2.5g，补充蒸馏水至100ml，即得所述水杨酸+冰片对照组。
炉甘石对照组：将炉甘石15g研细混匀，过100目筛子，补充蒸馏水至100ml，即得所述炉甘石对照组。
4.实验步骤
①取材方法：用棉签分别蘸取各实验组溶液，涂抹鼠尾，每日2次，14次为一疗程，末次涂抹后次日处死小鼠，在距鼠尾根部2cm处切断。在尽量避免损伤的情况下，切开皮肤，剥离软骨，取一长方形皮片贴附在滤纸上，立即投入10％的福尔马林中固定，常规脱水，香柏油透明，石蜡包埋、切片，苏木精-伊红染色法(hematoxylin-eosin staining，HE染色)。
②测定标准：在光学显微镜下对每个标本逐个测定鳞片厚度并观察棘层和颗粒层。具体方法:用血球记数盘(板)校正目镜测微尺，使在20倍物镜下1mm相当于50μm。用目镜测微尺测定表皮基底层部至角化层底部即表皮的厚度(尾鳞片)。每个皮片连续记数10个鳞片，每个鳞片测量10处鳞片表皮的厚度，得出每只小鼠的皮片共计100个尾鳞片表皮厚度的数值，并求出每组小鼠尾鳞片表皮厚度平均值。
③统计学处理：各组表皮厚度数据均以均数±标准差()表示。资料采用单因素方差分析进行检验，P>0.05表明无显著性差异，P<0.05表明有显著性差异，P<0.01表明有非常显著性差异。
正常情况下小鼠尾部鳞片表皮角质层角朊细胞保留有细胞核，而颗粒层颗粒细胞缺失，仅在毛囊处有少量的颗粒细胞，表皮较薄。鼠尾鳞片因表皮正常角化缺乏颗粒层，故可模拟银屑病(牛皮癣)角化不全的特点。药物如能促进鼠尾鳞片颗粒层形成，说明其可能改变表皮的角化过程，从角化不全恢复到正常角化，因此可能对银屑病(牛皮癣)具有治疗作用。
5.实验结果
结果如表1和图1、图2所示：玫瑰中药组合物涂抹小鼠尾部均有明显的诱导颗粒层增生、使表皮增厚的作用，尤其玫瑰中药组合物的高、中剂量组对小鼠尾部鳞片表皮颗粒层形成的促进作用显著(P<0.05)，优于水杨酸+冰片对照组、炉甘石对照组和中药组合物的低剂量组(表1)。本实验中玫瑰中药组合物涂抹小鼠尾部14天后，明显能促进鼠尾鳞片颗粒层形成，对银屑病(牛皮癣)具有治疗作用(图2)。
表1 小鼠尾鳞片表皮厚度(μm)的变化
通过以上实施例证明，本发明提供的玫瑰中药组合物具有清热解毒、祛风止痒的功效，对牛皮癣、湿疹及类似皮肤病具有治疗效果，且对皮肤无副作用，可在制备治疗牛皮癣的药物中应用，亦可在制备治疗湿疹的药物中应用。
Claims (4)
1.一种治疗牛皮癣的玫瑰中药组合物，其特征在于，所述中药组合物由下述重量比的组分组成：15-20份玫瑰花，1.5-2.5份水杨酸，0.75-1份维生素E，2.5-5份冰片，12.5-15份炉甘石。
2.如权利要求1所述的一种治疗牛皮癣的玫瑰中药组合物，其特征在于，所述中药组合物作为药效成分的药物制剂的剂型为霜剂、乳剂、膏剂、粉剂、洗剂、凝胶剂、气雾剂、涂膜剂、酊剂和醑剂。
3.如权利要求1所述的治疗牛皮癣的玫瑰中药组合物在制备治疗牛皮癣的药物中的应用。
4.如权利要求1所述的治疗牛皮癣的玫瑰中药组合物在制备治疗湿疹的药物中的应用。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610171345.2A CN105796690B (zh) | 2016-03-24 | 2016-03-24 | 一种治疗牛皮癣的玫瑰中药组合物及制备方法和应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610171345.2A CN105796690B (zh) | 2016-03-24 | 2016-03-24 | 一种治疗牛皮癣的玫瑰中药组合物及制备方法和应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105796690A CN105796690A (zh) | 2016-07-27 |
| CN105796690B true CN105796690B (zh) | 2018-01-16 |
Family
ID=56454377
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610171345.2A Active CN105796690B (zh) | 2016-03-24 | 2016-03-24 | 一种治疗牛皮癣的玫瑰中药组合物及制备方法和应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105796690B (zh) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107510596A (zh) * | 2017-07-05 | 2017-12-26 | 杨露萍 | 一种眼科用移动式防污染洗眼机 |
| CN108969678A (zh) * | 2018-10-11 | 2018-12-11 | 韩顺光 | 一种治疗慢性牛皮癣的外用中药组合物及其制备方法 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101513447A (zh) * | 2008-02-22 | 2009-08-26 | 卢明仁 | 治疗皮炎、癣病的药物 |
-
2016
- 2016-03-24 CN CN201610171345.2A patent/CN105796690B/zh active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN105796690A (zh) | 2016-07-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108553411B (zh) | 壬二酸凝胶剂及其制备方法和应用 | |
| CN101569640A (zh) | 积雪草总苷用于制备预防或治疗妊娠纹的药物或化妆品的用途 | |
| WO2024045952A1 (zh) | 含重组胶原蛋白具有修护舒缓功效的组合物、含有该组合物的眼霜及制备方法和应用 | |
| EP2954897B1 (en) | Skin-moisturising or wrinkle-improving external composition and cosmetic composition | |
| CN108143844A (zh) | 用于保养肌肤的表皮干细胞及具有多种功能的中草药组成物及其面膜 | |
| CN108704021A (zh) | 用于皮肤过敏及皮肤屏障受损的组合物及制备方法 | |
| CN103751530B (zh) | 一种具有抗敏功效的中药组合物的提取物及其应用 | |
| CN105796690B (zh) | 一种治疗牛皮癣的玫瑰中药组合物及制备方法和应用 | |
| CN111514055A (zh) | 一种具有抗炎修复功效的化妆品用多肽组合物颗粒剂 | |
| CN110652558A (zh) | 一种治疗化疗性静脉炎的中药水凝胶贴剂及其制备方法 | |
| CN106562894B (zh) | 美白、抗衰老、抗过敏的橙皮苷组合物及用途和制剂 | |
| CN101606898A (zh) | 五味子提取物在制备防晒护肤品中的应用 | |
| CN109125207A (zh) | 一种抑菌祛痘的植物复方组合物及其制备方法和应用 | |
| Builders et al. | Moringa oleifera ethosomes a potential hair growth activator: Effect on rats | |
| WO2019085852A1 (zh) | 一种祛除萎缩纹的组合物 | |
| CN106728168B (zh) | 一种治疗湿疹、银屑病的中药外用制剂及其制备方法 | |
| CN105125651A (zh) | 一种美白淡斑组合物及其制备方法、使用方法 | |
| CN109364290A (zh) | 一种薰衣草精油脂质体液体创可贴及其制备方法 | |
| CN108403932A (zh) | 一种治疗激素依赖性皮炎的中药复方外用制剂及其制备方法和应用 | |
| DE69727154T2 (de) | Land- und meeressschildkrötenöle, diese enthaltende zusammensetzungen, verfahren zu deren herstellung und verwendungen | |
| CN100441206C (zh) | 一种治疗皮肤烫、创伤和疮疡的复方药及其制备方法 | |
| US11154583B2 (en) | Composition and method of skin relief cream useful for eczema, psoriasis, lipoma, burn wounds, scars, keloids, shingles, dry skin disorders, and skin allergies | |
| Lavanya et al. | Aloe vera on skin. | |
| CN109939052B (zh) | 一种抗皮肤光老化作用的护肤组合物 | |
| CN109925248B (zh) | 一种含有根皮素、三七总皂苷抗皮肤光老化作用的护肤组合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |